Search Results
Results 401 - 450 of 1446
< 4 5 6 7 8 9 10 11 12 13 14 >
Yokoyama Masaki - - 2005
BACKGROUND: Plaque stabilization by statins is important for reduction of cardiovascular events but has not been demonstrated enough in vivo. We examined whether statins clinically alter the structure of coronary atherosclerotic plaques using intravascular ultrasound (IVUS) radio-frequency (RF) signal analysis. METHODS: Fifty consecutive patients undergoing percutaneous coronary intervention were enrolled. ...
Sprecher Dennis L - - 2005
BACKGROUND: Skin cholesterol has been associated with coronary artery disease, extent of angiographic disease and inflammatory markers such as hs-CRP. Based on these findings we sought to determine whether skin cholesterol was associated with myocardial infarction (MI). METHODS: Patients (N = 649) underwent diagnostic catheterization and concurrent skin cholesterol measurement. ...
Luc Gérald - - 2006
The pathogenesis of ischemic coronary events involves degradation of the extracellular matrix in atherosclerotic lesions. The cysteine protease inhibitor cystatin-C may be involved in this phenomenon. The association of plasma cystatin-C with the incidence of myocardial infarction-coronary death and angina, was examined in a nested case-control (two controls per case) ...
Schlitt Axel - - 2005
BACKGROUND: Lipoproteins and their subfractions are associated with the incidence of atherosclerotic diseases. In patients with coronary artery disease (CAD), low serum concentrations of high density lipoprotein (HDL) and high low-density lipoproteins (LDL) are correlated to myocardial infarction and cardiovascular death. There is growing evidence indicating that those lipoprotein factors ...
Marchioli R - - 2005
The purpose of this paper is twofold: on the one hand, to confirm the positive results on n-3 PUFA from the overall results Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GlSSI)-Prevenzione trial; on the other, to summarize and describe how the results of an important trial can help ...
Shaltoni Hashem M - - 2005
Data from studies on the benefits of statins in coronary artery disease patients in preventing recurrent primary and secondary cardiac endpoints, as well as ischemic strokes, imply the potential value of statins in recurrent ischemic stroke prevention without coronary artery disease symptoms or, by extension, primary ischemic stroke prevention. However, ...
Avanzas P - - 2005
In the last decade, compelling evidence has evolved at both the basic science and clinical level for the implication of inflammation in the pathogenesis of atherosclerosis and its complications. The composition of the atherosclerotic plaque, rather than the degree of stenosis, is now recognized as a pivotal feature in determining ...
Hackam Daniel G - - 2005
Patients with peripheral arterial disease are at greatly elevated risk for stroke and myocardial infarction and are six times more likely to die from cardiovascular causes than those without the disease. The available evidence supports the provision of an antiplatelet agent, a statin, and an angiotensin-converting enzyme inhibitor for cardiovascular ...
van Leuven Sander I - - 2005
The introduction of statins has drastically changed the treatment and prevention of atherosclerotic vascular disease. By lowering lipid levels and reducing the risk of coronary heart disease, these drugs are among the most effective at reducing morbidity and mortality available to clinical practice. In fact, these compounds have demonstrated the ...
Ray Kausik K - - 2005
Until recently, atorvastatin was known only as a new but more potent statin ('me too' drug) for lowering low-density lipoprotein cholesterol. In the last 2 years, data has become available on nearly 32,000 patients, in clinical settings ranging from primary prevention to acute coronary syndromes. These trials show the remarkably ...
Peskov A B - - 2005
The substrate composition containing succinic acid, substrates for succinate synthesis, and antioxidants increased the efficiency of pharmacotherapy in patients with coronary heart disease and hypertension. We revealed an increase in the quality of life and decrease in the functional class of heart failure, incidence of arrhythmias and exercise-related pain, and ...
Baessler A - - 2005
OBJECTIVES: The majority of patients with myocardial infarction (MI) and hypercholesterolaemia does not achieve guideline recommended low-density lipoprotein cholesterol (LDL) levels. Suboptimal dosages of statins explain this dilemma in most patients. DESIGN AND SETTING: We evaluated the relationship between statin treatment quality (optimal: LDL<115 mg/dl, suboptimal: LDL>/=115 mg/dl, no statin ...
Noto Davide - - 2005
BACKGROUND: Cystatin C is the most abundant protease inhibitor in the plasma. Low plasma levels have been found in patients with aortic aneurysms and they seem correlated with the extension of the aortic lesions in early aneurysms detected by ultrasonography. METHODS: In this study, plasma levels of cystatin C have ...
Moriarty Patrick M - - 2005
Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is a proinflammatory participant in atherosclerosis and a potential biomarker for coronary heart disease. The effects of low-density lipoprotein (LDL) apheresis on Lp-PLA(2) levels were evaluated in 8 patients with cardiovascular disease. Each patient received 5 LDL apheresis treatments over a 3-month period. The mean direct ...
Nagano Masahide - - 2005
A 54-year-old female was admitted to hospital complaining of oppressive anterior chest pain during exercise. Treadmill exercise ECG testing showed significant ischemic ECG changes, and electron-beam computed tomography demonstrated patchy calcifications in the coronary artery. Coronary angiography revealed a significant stenotic lesion of the right coronary artery. On routine investigations, ...
Zhou Zheng - - 2005
Clinical trials have shown the benefits of statins after acute myocardial infarction (AMI). However, it is unclear whether different statins exert a similar effect in reducing the incidence of recurrent AMI and death when used in clinical practice. We conducted a retrospective cohort study (1997-2002) to compare 5 statins using ...
Everett Charles J - - 2005
Principal component analysis was used to summarize variations among 7 lipid measures included in the Framingham Offspring Study (n = 2,694). An overall measure combining information from the 7 lipids was compared with conventional lipid measures in adjusted survival analyses and was found to be a superior predictor of coronary ...
Christ Michael - - 2006
AIMS: Previous studies indicate that low cholesterol levels are associated with adverse prognosis in heart failure patients, because elevated lipoprotein levels may negate bacterial endotoxin load induced by gastrointestinal congestion. METHODS AND RESULTS: We examined the prognostic significance of lipid levels in a cohort of 422 patients with idiopathic dilated ...
Stewart Ralph A H - - 2005
BACKGROUND: Elevated serum inflammatory marker levels are associated with a greater long-term risk of cardiovascular events. Because 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors (statins) may have an antiinflammatory action, it has been suggested that patients with elevated inflammatory marker levels may have a greater reduction in cardiovascular risk with statin treatment. METHODS ...
Bambauer Rolf - - 2005
Numerous epidemiological investigations have shown the importance of cholesterol, and in particular low density lipoprotein (LDL), and of the lipoproteins in the development of coronary sclerosis. A continuing relationship between cholesterol levels and coronary morbidity has been established. The LDL concentration in the blood is, in particular, to be made ...
Scuffham Paul - - 2005
The use of percutaneous coronary intervention to remove occlusions from coronary arteries has increased substantially over recent years. Concurrent with the use of percutaneous coronary intervention, the use of lipid-lowering medications, such as statins, has increased. The Lescol Intervention and Prevention Study showed significant reductions with statins in postpercutaneous coronary ...
Böhm M - - 2005
The effect of statins to reduce mortality and morbidity in primary and secondary prevention as well as in acute coronary syndrome is well established. Recent data show that pleiotropic effects might also have direct effects on the myocardial cell. However, in chronic heart failure the outcome is inversely related to ...
Longenecker J Craig - - 2005
Lipoprotein(a) [Lp(a)] levels are increased in dialysis patients, suggesting that they may play a role in the elevated atherosclerotic cardiovascular disease (ASCVD) risk in this population. Few prospective studies of Lp(a) level, apolipoprotein(a) [apo(a)] size, and ASCVD have been performed in the dialysis population. An inception cohort of 833 incident ...
Shimizu Masami - - 2005
BACKGROUND: Cholesterol lowering therapy may offset the development of coronary atherosclerosis, and the resulting reduction in coronary ischemia may be observed in the electrocardiogram (ECG). METHODS: A total of 2039 Japanese adults with hypercholesterolemia were divided into two groups (receiving 10-20 mg pravastatin daily or a normal diet) and were ...
Wright Douglas G - - 2005
Hypercholesterolemia is a major risk factor in the development of cardiovascular disease and HMG-CoA reductase inhibitors (i.e. statins) were originally designed to reduce serum cholesterol levels and thus reduce this risk factor. However, it has become increasingly apparent that the effects of statins extend well beyond their lipid lowering actions, ...
Ali Imtiaz S IS Division of Cardiac Surgery, Dalhousie University, Halifax, NS, Canada. - - 2005
Unstable angina (UA) is characterized by a state of coronary artery vascular inflammation and endothelial dysfunction. Statins mitigate inflammation and endothelial dysfunction and decrease mortality associated with percutaneous interventions for UA. We determined whether preoperative statin use is associated with decreased mortality and morbidity following coronary artery bypass+/-valve surgery for ...
Wolfram Roswitha - - 2005
The role of oxidation injury as an important factor in the pathophysiology of cardiomyopathy (CMP) has recently gained increasing interest. Semiquantitative analysis for isoprostane, 8-epi-prostaglandin F(2alpha) (8-epi-PGF(2alpha)), and oxidised low-density lipoprotein (ox-LDL) of coronary vascular tissue samples derived from CMP patients revealed an increased extent and intensity of uptake as ...
Ohtake Takayasu - - 2005
The prevalence of coronary artery stenosis (CAS) at the initiation of renal replacement therapy (RRT) in patients with chronic kidney disease (CKD) and no previous history of angina and/or myocardial infarction (MI) has not been fully elucidated. The prevalence of significant CAS was evaluated in 30 asymptomatic stage 5 CKD ...
Smith Donald A - - 2005
Eight case histories with differing clinical presentations and lipid abnormalities are presented to illustrate new trends in lipid management. Issues discussed include the use of coronary artery calcium scores to assess coronary heart disease risk for individuals who are asymptomatic, lower LDL-cholesterol goals, new lipid measurements that may be clinically ...
Ozer Kerem - - 2005
Atherosclerosis continues to account for significant morbidity and mortality in most of the world. The major proportion of atherosclerosis mortality is related to atherosclerotic coronary artery disease, yet there still is not an optimal method for making the diagnosis of vulnerable plaque in vivo. The search for such an undefined ...
Chiu John H - - 2005
Hydroxymethylglutaryl coenzyme-A reductase inhibitors, or statins, have been shown to decrease mortality rates in patients who have coronary artery disease. It has been postulated that part of the mortality benefit conferred by statins is due to a decrease in ventricular arrhythmias. We assessed the effect of statin therapy on recurrent ...
Winkler Karl - - 2005
BACKGROUND: Platelet-activating factor acetylhydrolase (PAF-AH), also denoted as lipoprotein-associated phospholipase A2, is a lipoprotein-bound enzyme that is possibly involved in inflammation and atherosclerosis. This study investigates the relationship of PAF-AH activity to angiographic coronary artery disease (CAD), the use of cardiovascular drugs, and other established risk factors. METHODS AND RESULTS: ...
Nagotani Shoko - - 2005
BACKGROUND AND PURPOSE: This study aimed to clarify the effect of statins on spontaneous stroke and to examine the antioxidative effect in artificial transient middle cerebral artery occlusion (tMCAO). METHODS: Stroke-prone spontaneous hypertensive rats (SHR-SP) were treated with pitavastatin, atorvastatin, simvastatin, or vehicle for 4 weeks. Physiological parameters, serum lipids, ...
Rondina Matthew T - - 2005
Acute coronary syndromes (ACS), such as myocardial infarction and unstable angina, are leading causes of death in developed countries. The risk of recurrent adverse events, rehospitalization, and death remain high in the weeks to months following ACS. Large secondary prevention trials have shown that the initiation of statin therapy within ...
Doo Young-Cheoul - - 2005
BACKGROUND: Statins are believed to reduce coronary heart disease by mechanisms in addition to their well-known cholesterol lowering effect. HYPOTHESIS: We studied the effect of statins on expression of C-reactive protein (CRP), interleukin-6 (IL-6), adhesion molecules, and antioxidized low-density lipoprotein antibody (anti-oxLDL Ab) in patients with unstable angina (Braunwald class ...
Schouten Olaf - - 2005
PURPOSE OF REVIEW: This is a review of recent experimental and clinical evidence for the use of perioperative statins to reduce cardiovascular complications. RECENT FINDINGS: Clinical trials have demonstrated an improved survival of statin users in the perioperative period. This beneficial effect of statins is ascribed to the non-lipid lowering ...
O'Neil-Callahan Kristin - - 2005
OBJECTIVES: We sought to assess whether statins may decrease cardiac complications in patients undergoing noncardiac vascular surgery. BACKGROUND: Cardiovascular complications account for considerable morbidity in patients undergoing noncardiac surgery. Statins decrease cardiac morbidity and mortality in patients with coronary disease, and the beneficial treatment effect is seen early, before any ...
Von Eyben Finn Edler - - 2005
The association between plasma fibrinogen concentration and other coronary risk factors diverged in previous studies, and the impact from complex lipoprotein patterns has not been studied. Our research involved 24 healthy subjects without coronary heart disease (control) and 22 patients who had survived having acute myocardial infarction before the age ...
Canner Paul L - - 2005
The Coronary Drug Project, conducted during 1966 to 1974, was a randomized, double-blind, placebo-controlled trial of 5 lipid-modifying agents in 8,341 men with previous myocardial infarction. Among the 5 drug treatment regimens, only niacin significantly reduced the risk of (1) cardiovascular events during a mean follow-up of 6.2 years and ...
Bocksch Wolfgang - - 2005
Lipid-lowering therapy has a significant impact on the prognosis and clinical course of coronary artery disease (CAD). Slowdown of plaque progression and plaque stabilization are the major cardiac goals of any lipid-lowering strategy. Until now, intravascular ultrasound imaging (IVUS) has been the only in vivo imaging modality which allows serial ...
Bevilacqua M - - 2005
The increasing knowledge on bone calcification processes has revealed some similarities with vascular tissue, where calcifications of arteries and cardiac valves contribute to several cardiovascular problems, such as heart failure, systolic hypertension, and myocardial and peripheral ischemic disease. Bisphosphonates have been used extensively for over two decades for the treatment ...
Yan Bernard - - 2005
BACKGROUND: Although acute decreases in total cholesterol (TC) are well documented in myocardial infarction, previous stroke studies have produced conflicting results. The timing of lipid estimation in ischemic stroke is becoming important with recent trial results indicating the benefits of statins. We therefore aimed to determine the optimal time for ...
Daskalopoulou Stella S - - 2005
Peripheral arterial disease (PAD) is a common condition associated with an increased risk of coronary heart disease, myocardial infarction and stroke. It follows that PAD merits aggressive preventive treatment that includes lipid lowering drugs (mainly statins). This review summarises the current knowledge concerning the use and mechanisms of action of ...
Fang Chun-Hong - - 2005
It is estimated that about 1 million patients are hospitalized for acute coronary events each years in the United States. An acceptable theory is that the acute coronary syndrome is caused by rupture of the atherosclerotic plaque with superimposed thrombus, which is a complex process and involving a number of ...
Al Aqeel A - - 2005
OBJECTIVE: To evaluate the American College of Cardiology/American Heart Association guidelines on blood lipid testing within 24 h of the onset of chest pain in patients with myocardial infarction. SUBJECTS AND METHODS: This is a cross-sectional observational study on 83 patients (77 male, 6 female) admitted into the Coronary Care ...
Clader John W - - 2005
Atherosclerotic coronary artery disease remains a major healthcare concern especially in developed countries. While lowering plasma cholesterol levels via diet, exercise, and pharmacotherapy can reduce this risk of developing coronary artery disease, there remains a need for more effective drug therapies. The azetidinone cholesterol absorption inhibitors typified by ezetimibe represent ...
Scalia Rosario - - 2005
The benefits of long-term statin (HMG-CoA reductase inhibitor) treatment for preventing coronary events have been well documented in several large-scale prospective clinical trials. By influencing the determinants of myocardial injury, statins may produce direct cardioprotective effects in the ischemic myocardium and prevent further damaging recurrent events. Although not proven fully ...
Paoletti R - - 2005
Long- and short-term trials with the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have demonstrated significant reductions in cardiovascular events in patients with and without history of coronary heart disease. Statins are well-established low-density lipoprotein (LDL)-lowering agents, but their clinical benefit is believed to result from a number of lipid and ...
Mullenix Philip S - - 2005
Atherosclerosis has traditionally been attributed to disordered cholesterol metabolism with associated accumulation of lipid substrate in the arterial wall. It is now believed that systemic and local inflammatory events mediate all phases of plaque development, progression, and degeneration. No longer regarded as a bland, mechanical process, plaque evolution is now ...
Ostadal Petr - - 2005
Statins are cholesterol-lowering drugs, highly effective in the primary and secondary prevention of coronary artery disease. It has been found, however, that statins also have nonlipid effects; they can influence different pathways, which have been described to participate in the pathogenesis of acute coronary syndrome (ACS). Inflammation or decreased production ...
< 4 5 6 7 8 9 10 11 12 13 14 >